Cost-effectiveness of fondaparinux vs. enoxaparin as venous thromboembolism prophylaxis in Sweden

European Journal of Health Economics

Volumn 4, Issue 4, 2003, Pages 254-262

  Lundkvist, Jonas ^a   Bergqvist, David ^b   Jönsson, Bengt ^c  

^a STOCKHOLM HEALTH ECONOMICS   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cost effectiveness; Deep vein thrombosis; Pulmonary embolism; Surgery; Venous thrombosis

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX;

ARTICLE; BLEEDING; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG COST; HEALTH CARE COST; HIP FRACTURE; HUMAN; LUNG EMBOLISM; MAJOR SURGERY; MORBIDITY; MORTALITY; PRIORITY JOURNAL; SIMULATION; SURGICAL RISK; SWEDEN; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 0347755003     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0175-4     Document Type: Article

References (58)

1. Oster G, Tuden RL, Colditz GA (1987) A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. JAMA 257:203-208
2. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Post-operative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 359:1721-1726
3. Norgren L, Rosfors S, Ivancev K, Plate G, Johnsson H (2000) [Deep venous thrombosis-news on diagnostics and treatment]. Lakartidningen 97:1411-1412
4. Bergqvist D, Jendteg S, Johansen L, Persson U, Odegaard K (1997) Cost of long-term complications of deep venous thrombosis of the lower extremities: an analysis of a defined patient population in Sweden. Ann Intern Med 126:454-457
5. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB (1995) Prevention of venous thromboembolism. Chest 108:3125-345
6. Haake DA, Berkman SA (1989) Venous thromboembolic disease after hip surgery. Risk factors, prophylaxis, and diagnosis. Clin Orthop 242:212-231
7. National Board of Health and Welfare (2002) Medicinsk faktadatabas (in Swedish) Socialstyrelsen: Stockholm
8. National Board of Health and Welfare (2002) National inpatient care statistics. Socialstyrelsen: Stockholm
9. Anonymous (2001) Arsrapport Svenska knäplastikregistret (in Swedish)
10. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, et al (1999) Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. J Bone Joint Surg Am 81:932-940
11. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS (1998) The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty: a cohort study of 1:984 patients. Canadian Collaborative Group. Chest 114:1155-1185
12. Bergqvist D, Jonsson B (2000) Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement. Haemostasis 30:130-135
13. Balen RM, Marra CA, Zed PJ, Cohen M, Frighetto L (1999) Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes. A Canadian hospital perspective. Pharmacoeconomics 16:533-542
14. Bergqvist D (2002) Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. Pharmacoeconomics 20:225-243
15. Menzin J, Colditz GA, Regan MM, Richner RE, Oster G (1995) Cost-effectiveness of enoxaparin vs low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery. Arch Intern Med 155:757-764
16. Saunders ME, Grant RE (1998) Cost effectiveness of low-molecular weight heparin versus warfarin following hip replacement surgery. J Natl Med Assoc 90:677-680
17. Bauer KA, Eriksson BI, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 345:1305-1310
18. Eriksson BI, Bauer KA, Lassen MR, Turpie AG (2001) Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 345:1298-1304
19. Lassen MR, Bauer KA, Eriksson BI, Turpie AG (2002) Post-operative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 359:1715-1720
20. Turpie AG, Bauer KA, Eriksson BI, Lassen MR (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833-1840
21. National Corporation of Swedish Pharmacies (1999) Sale statistics. Apoteket AB: Stockholm
22. Outcomes and costs of prophylaxis against venous thromboembolism in patients undergoing major orthopedic surgery. Final technical report (2001) Policy Analysis Inc (PAI): Massachusetts
23. Gordois A, Posnett J, Borris L, Bossuyt P, Jönssson B, Levy E, et al (2002) The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis against venous thromboembolism following major orthopaedic surgery (abstract). Value Health 5:444
24. Sullivan S, Kahn S, Davidson B, L. B, Bossuyt P, Raskob G (2002) Measuring the outcomes and economic consequences of venous thromboembolism prophylaxis in major orthopedic surgery. Pharmacoeconomics (in press)
25. Planes A, Vochelle N, Darmon JY, Fagola M, Bellaud M, Huet Y (1996) Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 348:224-228
26. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W (1998) Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 158:1525-1531
27. Hull R, Raskob G, Pineo G (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329:1370-1376
28. Leclerc JR, Gent M, Hirsh J, Geerts WH, Ginsberg JS (1998) The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: a multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Canadian Collaborative Group. Arch Intern Med 158:873-878
29. Lubinus P, Klauser W (2001) Mortality after total hip replacement due to fatal pulmonary embolism. Abstract 114.1st SICOT/SIROT Annual International Conference, Paris
30. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, et al (2001) Prevention of venous thromboembolism. Chest 119:1325-1755
31. McNally MA, McAlinden MG, O'Connell BM, Mollan RA (1994) Postphlebitic syndrome after hip arthroplasty. 43 patients followed at least 5 years. Acta Orthop Scand 65:595-598
32. Pulmonary Embolism Prevention Trial Collaboration Group (2002) Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 355:1295-1302
33. Hansson PO, Sorbo J, Eriksson H (2000) Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 160:769-774
34. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1-7
35. Ginsberg JS, Turkstra F, Buller HR, MacKinnon B, Magier D, Hirsh J (2000) Postthrombotic syndrome after hip or knee arthroplasty: a cross-sectional study. Arch Intern Med 160:669-672
36. Siragusa S, Beltrametti C, Barone M, Piovella F (1997) [Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombosis. Results of a transverse epidemiologic study]. Minerva Cardioangiol 45:57-66
37. Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar W (1996) Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 20:521-526-
38. Hull R, Delmore T, Carter C, Hirsh J, Genton E, Gent M, et al (1982) Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 306:189-194
39. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al (1982) Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 307:1676-1681
40. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U (1985) Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 11:515-518
41. Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T, et al (1994) Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72:191-197
42. Heit JA, Elliott CG, Trowbridge AA, Morrey BF, Gent M, Hirsh J (2000) Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 132:853-861
43. Pellegrini VD Jr, Clement D, Lush-Ehmann C (1996) Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop 333:27-40
44. Anonymous (2002) Regional hospital price lists. County Councils in Sweden
45. Bergqvist D, Benoni G, Bjorgell O, Fredin H, Hedlundh U, Nicolas S, et al (1996) Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 335:696-700
46. Eriksson BI, Ekman S, Lindbratt S, Baur M, Bach D, Torholm C, et al (1997) Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 79:326-333
47. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, et al (1997) A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 337:1329-1335
48. LINFO (2001) FASS Läkemedel i Sverige. Läkemedelsinformation AB: Oslo
49. Anonymous (1996) Kostnad per intagen patient (in Swedish). Federation of County Councils: Stockholm
50. Bergqvist D, Jönsson B (1999) Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health 2:288-294
51. Bounameaux H, Perneger T (2002) Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 359:1710-1711
52. Eikelboom JW, Quinlan DJ, Douketis JD (2001) Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 358:9-15
53. Heit JA (2002) The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgery. Arch Intern Med 162:1806-1808
54. Hughes SJ (2003) Fondaparinux requires further study before firm recommendation. Arch Intern Med 163:498
55. Vormfelde SV (2002) Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery. Lancet 360:1701
56. Schulman S, Rhedin AS, Lindmarker P, Carlsson A, Larfars G, Nicol P, et al (1995) A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 332:1661-1665
57. Anonymous (2002) Life tables. Statistic Sweden: Stockholm
58. Todd CJ, Freeman O, Camilleri-Ferrante C, Palmer CR, Hyder A, Laxton CE, et al (1995) Differences in mortality after fracture of hip: the East Anglian audit. BMJ 310:904-908